Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avandia Retaining Preferred Status On 2008 Part D Formularies – For Now

Executive Summary

So far GlaxoSmithKline's Avandia (rosiglitazone) appears to be retaining its tier 2 status on the 2008 formularies of major Medicare Part D plans despite safety concerns that surfaced earlier this year

You may also be interested in...



Fosamax Formulary Analysis: Health Plans Shift Tiers Or Delete Brand

A number of major health insurers are in the process of moving Merck's Fosamax (alendronate) to higher cost-sharing tiers or off formularies altogether following the recent launch of generic competitors

Drug Reimbursement In Brief From Pharma Earnings Calls

Formulary access for Lipitor: "Our access remains in the range of 65 to 70 [percent] at tier 2 across commercial and Medicare lives," Pfizer Worldwide Pharmaceutical Operations President Ian Read commented during the firm's third quarter earnings call Oct. 18. Noting that U.S. prescriptions for the cholesterol reducer were down about 13 percent compared to 2006, he pointed out that losses from patient switches to generics have "stabilized" and the product's new patient volume is "fluctuating at around a 20 percent share." Lipitor's third quarter revenues declined 3 percent to $3.2 billion versus the comparable 2006 quarter...

Drug Reimbursement In Brief From Pharma Earnings Calls

Formulary access for Lipitor: "Our access remains in the range of 65 to 70 [percent] at tier 2 across commercial and Medicare lives," Pfizer Worldwide Pharmaceutical Operations President Ian Read commented during the firm's third quarter earnings call Oct. 18. Noting that U.S. prescriptions for the cholesterol reducer were down about 13 percent compared to 2006, he pointed out that losses from patient switches to generics have "stabilized" and the product's new patient volume is "fluctuating at around a 20 percent share." Lipitor's third quarter revenues declined 3 percent to $3.2 billion versus the comparable 2006 quarter...

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS048929

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel